Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma

被引：17
|
作者：
Axel, Amy E. [1 ]
McCudden, Christopher R. [2 ]
Xie, Hong [1 ]
Hall, Brett M. [1 ]
Sasser, A. Kate [1 ]
机构：
[1] Janssen R&D, Spring House, PA USA
[2] Ottawa Hosp, Ottawa, ON, Canada
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2563
引用
下载
收藏
页数：1
相关论文
共 17 条
  • [11] Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
    Agoston Gyula Szabo
    Tobias Wirenfeldt Klausen
    Niels Abildgaard
    Henrik Gregersen
    Trine Silkjær
    Per Trøllund Pedersen
    Robert Schou Pedersen
    Carsten Helleberg
    Emil Hermansen
    Brian Iversen Schnack
    Annette Juul Vangsted
    Blood Cancer Journal, 11
  • [12] Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response
    Bruno, Rene
    Jonsson, Fredrik
    Zaki, Mohamed
    Jacques, Christian
    Swern, Arlene S.
    Richardson, Paul G.
    Rajkumar, Vincent
    Claret, Laurent
    BLOOD, 2011, 118 (21) : 821 - 822
  • [13] Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: Validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Kumar, S
    Gertz, MA
    Hayman, SR
    Lacy, MQ
    Dispenzieri, A
    Zeldenrust, SR
    Lust, JA
    Greipp, PR
    Kyle, RA
    Fonseca, R
    Rajkumar, SV
    BLOOD, 2005, 106 (11) : 971A - 971A
  • [14] Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein
    Curtin, Francois
    Perron, Herve
    Kromminga, Arno
    Porchet, Herve
    Lang, Alois B.
    MABS, 2015, 7 (01) : 265 - 275
  • [15] Early Clinical Development of GNBAC1 a Humanized Monoclonal Antibody Neutralizing MSRV-ENV, a Neurotoxic Protein, for the Treatment of Multiple Sclerosis
    Peter, Hartung Hans
    Perron, Herve
    Lang, Alois
    Porchet, Herve
    Curtin, Francois
    NEUROLOGY, 2016, 86
  • [16] Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment (vol 37, pg 1, 2023)
    Claveau, Jean-Sebastien
    Murray, David L.
    Dispenzieri, Angela
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Dingli, David
    Fonder, Amie
    Gertz, Morie
    Gonsalves, Wilson
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, Vincent
    Kumar, Shaji K.
    LEUKEMIA, 2024, 38 (08) : 1863 - 1863
  • [17] A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
    Wichert, Stina
    Juliusson, Gunnar
    Johansson, Asa
    Sonesson, Elisabeth
    Teige, Ingrid
    Wickenberg, Anna Teige
    Frendeus, Bjorn
    Korsgren, Magnus
    Hansson, Markus
    PLOS ONE, 2017, 12 (02):
12